Phage-display VHH antibody screening service to develop in vivo gene therapy
Ended Purchase Order Awarded Last action
- Contract number
- 75N92024P00256
- Awardee
-
Proteogenix UEI CP2GCU4XTVM7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $29,700
Award facts
- Contract value 100% obligated
- $29,700.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- France
Award details come from SAM.gov/FPDS.
About this award
This is a $29,700.00 Firm Fixed Price purchase order contract awarded by the National Heart Lung and Blood Institute, a civilian agency, to Proteogenix, a for-profit manufacturer, for a phage-display VHH antibody screening service to develop in vivo gene therapy. The contract has an ultimate completion date of August 6, 2025. The contract was awarded on August 7, 2024 and does not have a set-aside designation.
Quick answers
Who was awarded contract 75N92024P00256?
75N92024P00256 was awarded to Proteogenix by National Heart Lung and Blood Institute (National Institutes of Health) on August 7, 2024.
How much is contract 75N92024P00256 worth?
The government has obligated $29,700 on 75N92024P00256.
Was contract 75N92024P00256 competed?
The extent of competition for 75N92024P00256 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award